9 results about "Nasal Drops" patented technology

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

This invention relates to the field of plant-derived extracellular vesicles, and discloses a method for preparing and applying Hypericum perforatum-derived exosome-like nanovesicles (HPDENs). This invention prepares HPDENs with natural vesicle structures through a specific process, utilizing the natural characteristics of plant-derived vesicles to encapsulate Hypericum perforatum (…). HP The active ingredient, combined with nasal drops, achieves targeted delivery to the brain. It exerts its antidepressant effect by regulating microglia polarization imbalance and reshaping the "neuroimmune-synaptic" axis. This solves the core problems of traditional antidepressants, such as slow onset of action, poor treatment response, and large side effects. It can also improve the core pathological features of depression (neuritis, synaptic plasticity damage) and improve depressive-like behaviors, providing a brand-new option for the clinical treatment of depression.

This invention relates to an engineered mesenchymal stem cell exosome complex, comprising mesenchymal stem cell exosomes and siRNA loaded on the mesenchymal stem cell exosomes. The invention also relates to a nasal drop formulation comprising the aforementioned exosome complex, which can be used to prepare a drug for treating bronchopulmonary dysplasia. The complex and formulation of the present invention possess unique advantages such as enhanced therapeutic specificity through targeted gene silencing, stable pulmonary vascular pathological repair effects, and engineered targeted therapy.

The application discloses a kind of nasal drops based on drug-loaded pollen for rhinitis and its preparation method and application, belong to the field of biomedical materials;The nasal drops include drug-loaded pollen microcarrier and pharmaceutically acceptable adjuvant;The drug-loaded pollen microcarrier is natural sunflower pollen particle with hollow cavity and surface thorn structure, and the cavity is loaded with the drug for treating allergic rhinitis.In the preparation method, sunflower pollen is washed, defatted with acetone diethyl ether, and treated with phosphoric acid cleavage to obtain pollen microcarrier with hollow outer thorn;Then, small molecule drugs are loaded under vacuum and reduced pressure;Finally, the adjuvant is mixed to prepare the drops.The application utilizes the natural "internal cavity and external thorn" structure of pollen, realizes efficient adhesion and sustained-release drug delivery in nasal cavity, and effectively resists cilia clearance.The pollen microcarrier removes allergenic proteins, has good biocompatibility, and does not aggravate allergic rhinitis.The application is low in cost and simple in operation, and provides a safe and efficient new platform for nasal drug delivery.

This invention provides a poultry immunization device, comprising a body, a clamping unit and an eye / nasal drop unit disposed on one side of the bottom of the body, and an injection unit disposed on the other side of the bottom of the body. The injection unit is connected to the clamping unit and the eye / nasal drop unit via pipes. Protective shielding units are disposed on the surfaces of the clamping unit and the eye / nasal drop unit. A buffer storage compartment is disposed at the bottom of the clamping unit and the eye / nasal drop unit to temporarily store the immunized poultry. A control unit is disposed at the top of the body, and the control unit is signal-connected to the clamping unit, the injection unit, and the eye / nasal drop unit. The clamping unit facilitates operation, ensures accurate immunization injection, and provides a suitable clamping position for the poultry. Furthermore, it ensures high operational safety, as the poultry automatically moves up and down after being clamped, avoiding the risk of accidental injury to the operator.

The embodiment of the application discloses a method for constructing a human respiratory syncytial virus newborn mouse infection model and application thereof.The method comprises the following steps: inoculating a virus liquid containing a human respiratory syncytial virus (RSV) into a 3-day-old SPF healthy BALB / c newborn mouse through nasal drops, and obtaining the human respiratory syncytial virus newborn mouse infection model after 4-5 days.The application successfully establishes a newborn mouse infection model which is simple to operate, good in repeatability and closer to clinical pathological characteristics.The model has the advantages of high virus infection rate, high similarity of pathological characteristics to human newborn infection, simple model construction method, short cycle, low cost, good stability and strong repeatability, and has a wide application prospect in RSV related research and development.

The application discloses a preparation method of a nasal drop with traditional Chinese medicine biological components for treating rhinitis, and comprises the following steps: step one, preparing the first type of nasal drop: frying Semen Xanthii is matched with Magnolia and Bai Zhi to prepare the first type of nasal drop; step two, preparing the second type of nasal drop: using Mentha with Chrysanthemum and Forsythia to prepare the second type of nasal drop; step three, preparing the third type of nasal drop: matching Huangqi with Baishu and Fangfeng to prepare the second type of nasal drop; step four, preparing the finished product: mixing the prepared first type of nasal drop, the second type of nasal drop and the third type of nasal drop to obtain the finished product, wherein the raw materials of the nasal drop are all traditional Chinese medicines, the traditional Chinese medicine preparation has the characteristics of safety and reliability, easy purchase of raw materials, moderate price and easy production, and the traditional Chinese medicine preparation has the characteristics of broad-spectrum treatment of rhinitis, replacement of traditional hormone treatment, reduction of damage of the medicine to the human body and high safety.

This invention relates to the field of traditional Chinese medicine antibacterial liquid technology, and particularly to a traditional Chinese medicine antibacterial liquid for nasal use, made from the following raw materials: Xanthium sibiricum, Centipeda minima, Magnolia biondii, Asarum heterotropoides, Acorus tatarinowii, Akebia trifoliata, Atractylodes lancea, Indigo naturalis, Mentha haplocalyx, and polyhexamethylene biguanide. This invention combines nine traditional Chinese medicines—Xanthium sibiricum, Centipeda minima, Magnolia biondii, Asarum heterotropoides, Acorus tatarinowii, Akebia trifoliata, Atractylodes lancea, Indigo naturalis, and Mentha haplocalyx—with polyhexamethylene biguanide. The traditional Chinese medicine components are an improvement on the ancient formula of Xanthium sibiricum powder, synergistically exerting the effects of clearing the lungs and nasal passages, dispelling wind and cold, and anti-inflammatory and anti-allergic properties. Polyhexamethylene biguanide provides broad-spectrum antibacterial efficacy. By changing the traditional oral dosage form to a nasal drop, the liquid acts directly on the nasal mucosa lesion site, avoiding the first-pass effect of the liver and the metabolic burden on the kidneys associated with oral medications, significantly improving drug safety. Skin irritation, eye irritation, and allergy tests all showed no irritation or sensitization.

This invention provides a subunit vaccine containing Mycoplasma pneumoniae HP14 / 30 fusion antigen and a mucosal adjuvant. The subunit vaccine comprises the Mycoplasma pneumoniae HP14 / 30 fusion antigen and a mucosal adjuvant in a mass ratio of 1-5:1. The HP14 / 30 fusion antigen is a recombinant protein co-expressed by chimeric fragments of the P1 and P30 proteins, with the amino acid sequence shown in SEQ ID NO:1. This vaccine is administered via mucosal routes such as nasal drops or oral inhalation. It efficiently induces respiratory mucosal-specific IgA and humoral IgG responses, significantly reduces pathogen load in the lungs, alleviates pathological damage to lung tissue, and does not induce enhanced respiratory disease (ERD). Its safety and protective efficacy are significantly superior to traditional inactivated vaccines and intramuscular vaccines. This invention fills the technological gap in human Mycoplasma pneumoniae subunit vaccines, is suitable for the prevention of Mycoplasma pneumoniae infection in children and adults, and has significant clinical application value.